- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02395783
Therapeutic Effects of Maternal Melatonin Administration on Brain Injury and White Matter Disease (PREMELIP)
Therapeutic Effects of Maternal Melatonin Administration on Brain Injury and White Matter Disease in Very Preterm Infants
Neurocognitive sequelae observed in preterm represent a major health problem for which there is no preventive treatment approved to date. These effects are the result of a multifactorial brain damage occurring in developing prenatal and perinatal period. Melatonin, the principal hormone secreted by the pineal gland has neuroprotective properties in various experimental animal models of perinatal brain damage level. This hormone readily crosses the placental barrier, its antenatal administration would have a neuroprotective effect in the case of preventive preterm birth before 28 weeks of amenorrhea.
The objective of this study determine the dose of melatonin administered parenterally in prenatal maternal in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) with statistical spatial analysis (TBSS) to the theoretical term of 40 weeks in children born prematurely.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Neurocognitive sequelae observed in preterm represent a major health problem for which there is no preventive treatment approved to date. These effects are the result of a multifactorial brain damage occurring in developing prenatal and perinatal period. Melatonin, the principal hormone secreted by the pineal gland has neuroprotective properties in various experimental animal models of perinatal brain damage level. This hormone readily crosses the placental barrier, its antenatal administration would have a neuroprotective effect in the case of preventive preterm birth before 28 weeks of gestation.
The objective of this study determine the dose of melatonin administered parenterally in prenatal maternal in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) with statistical spatial analysis (TBSS) to the theoretical term of 40 weeks in children born prematurely.
Secondary objectives:
- Determine the pharmacokinetics of melatonin administered intravenously in two dosage regimens and after randomization in pregnant women under 28 weeks
- Assess the contribution of antenatal injection of melatonin on the incidence of white matter injury detected by conventional brain MRI
- Assess the contribution of antenatal injection of melatonin on the rate of neurological sequelae at 2 years corrected age, mortality at 28 days of life and at the end of hospitalization.
Evaluate the adverse effects of melatonin injection
- Selection criteria (inclusion and non-inclusion)
Inclusion criteria:
- gestational age between 24 weeks + 0 and 27 weeks + 6 days
- Delivery imminent spontaneous defined by cervical dilation greater than or equal to 3 cm and regular contractions, painful (greater than or equal to 2 every 10 minutes) or elective caesarean section.
- maternal age ≥18 years at baseline
- written consent and
- Joining a social security scheme mother and holders of parental authority
Criteria for non-inclusion
Related to the parent criteria:
- Delivery Outborn
- Magnesium Sulphate injection in mother
- Chronic renal and hepatic impairment before pregnancy
- Circumstances of maternal or fetal distress requiring emergency cesarean eclampsia, placental abruption, placenta previa bleeding.
Criteria related to the fetus:
diagnosis of antenatal malformation Number of subjects required 60 pregnant women between 24 weeks + 0 and 27 weeks + 6 days
- Search time, duration of participation of each patient Total study duration: 36 months Inclusion period: 12months Duration of participation for a patient 24 months Number of participating centers: 3 Average number of inclusions per month per center: 3
- Methodology Clinical phase Iib, 3-arms, double-blind randomised controlled trial, multicenter
- Exams required specifically for research (blood, biopsy ...)
- Treatment: antenatal injection of melatonin ((maximum of 2 doses of 10 mcg or 20 mcg)) against placebo in the delivery room
Reviews:
- Determination of plasma melatonin before, after the injection of melatonin (5 minutes, 1 hour, 3 hours, 4 hours after birth) in the mother
- Determination of plasma melatonin and serotonin in umbilical cord
- Brain MRI with diffusion tensor sequence (spatial analysis statistiqueTBSS) at 40 weeks • Primary endpoint and secondary endpoints
Primary endpoint:
MRI with diffusion tensor sequence (TBSS analysis).
Standard (s) Secondary Outcome (s):
- Pharmacokinetics of melatonin in the mother
- Determination of plasma melatonin and serotonin in umbilical cord f
- Brain lesions by conventional MRI
- Neurological Evaluation at the age of 2 years by the revised Brunet-test skimped
- Mortality at 28 days of life and at discharge
- Tolerance of melatonin in pregnant women
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75019
- Hopital Robert Debre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- gestational age between 24 weeks + 0 and 27 weeks + 6 days
- Delivery imminent spontaneous defined by cervical dilation greater than or equal to 3 cm and regular contractions, painful (greater than or equal to 2 every 10 minutes) or elective caesarean section.
- maternal age ≥18 years at baseline
- written consent and
- Joining a social security scheme mother and holders of parental authority
Exclusion Criteria:
- Related to the parent criteria:
- Delivery Outborn
- Magnesium Sulphate injection in mother
- Chronic renal and hepatic impairment before pregnancy
- Circumstances of maternal or fetal distress requiring emergency cesarean eclampsia, placental abruption, placenta previa bleeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
|
Active Comparator: Melatonin dose1
Melatonin 10 µg
|
Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
|
Active Comparator: Melatonin dose2
Melatonin 20 µg
|
Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TBSS analysis
Time Frame: 40 weeks
|
The primary endpoint will be the analysis of white matter injury (LSB) at 40 weeks corrected by brain MRI with diffusion tensor sequence (TBSS analysis).
|
40 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
measurement of plasma melatonin levels
Time Frame: before injection of the drug, 5 minutes, 1 hour, 3 hours, 4 hours and 5 hours after injection of the drug
|
Pharmacokinetics of melatonin in the mother to determine the dose of Melatonin supplementation in pregnant women (between 24 weeks and 27 weeks + 6days)
|
before injection of the drug, 5 minutes, 1 hour, 3 hours, 4 hours and 5 hours after injection of the drug
|
Plasma melatonin level
Time Frame: Day 1
|
Plasma melatonin level measured in the mother and the newborn at birth (cord blood)
|
Day 1
|
Neurological evaluation (revised Brunet-test)
Time Frame: 2 years
|
Neurological evaluation at the age of 2 years by the revised Brunet-test skimped
|
2 years
|
Mortality
Time Frame: 28 days of life
|
Mortality at 28 days of life and at discharge
|
28 days of life
|
Collaborators and Investigators
Investigators
- Principal Investigator: Biran Valérie, PHD, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Craniocerebral Trauma
- Trauma, Nervous System
- Pregnancy Complications
- Obstetric Labor Complications
- Obstetric Labor, Premature
- Brain Injuries
- Premature Birth
- Leukoencephalopathies
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Protective Agents
- Antioxidants
- Melatonin
Other Study ID Numbers
- P120113
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Premature Birth
-
Shaare Zedek Medical CenterTerminatedPremature Birth of NewbornIsrael
-
University of VirginiaCompletedPremature Birth of NewbornUnited States
-
Case Western Reserve UniversityCompleted
-
University of California, San FranciscoUniversity of California, San Diego; University of California, Los Angeles; Kaiser...CompletedPremature Birth of NewbornUnited States
-
Universitaire Ziekenhuizen KU LeuvenKU LeuvenUnknownPremature Birth of NewbornBelgium
-
Universidad Complutense de MadridCompletedPremature Birth of Newborn
-
Indiana UniversityCompletedPremature LaborUnited States
-
Washington University School of MedicineUniversity of Southern CaliforniaCompletedPremature Birth of NewbornUnited States
-
Vestre Viken Hospital TrustHaukeland University HospitalActive, not recruiting
-
University of ArkansasCompletedPremature Birth of NewbornUnited States
Clinical Trials on Melatonin 10 µg
-
RVAC Medicines (US), Inc.TerminatedCOVID-19 | Infectious DiseaseAustralia
-
HealOrUnknownHard to Heal WoundsIsrael
-
AllerganCompletedOcular Hypertension | Open-Angle GlaucomaUnited States, Israel, Canada, Singapore, Philippines, Spain, Australia, Belgium, Brazil, Germany
-
Health DecisionsEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
BioNTech SEPfizerActive, not recruitingCOVID-19 | SARS-CoV-2 InfectionUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
Institut PasteurWellcome Trust; Walter Reed Army Institute of Research (WRAIR); Parexel; Bill &... and other collaboratorsCompleted
-
Aalborg UniversityCompletedItch | Papain | Skin Prick Test (SPT)Denmark
-
Imperial College LondonGlaxoSmithKlineCompleted
-
SanofiCompletedClostridium InfectionsUnited States